CEOs cutting ribbon at opening ceremony
John Anson CEO, OGT and Mr. Kaoru Asano, Member of the Managing Board and Senior Executive Officer, Sysmex

Source: OGT

News • New at Science Park

OGT celebrates opening of new Cambridge site

Oxford Gene Technology (OGT), A Sysmex Group Company, has celebrated the opening of its new facility in Cambridge, UK.

The opening ceremony, which took place at the company’s new premises on the prestigious Cambridge Science Park, was attended by the Department for International Trade (DIT) and local media as well as top-level representatives from OGT and its parent company, Sysmex Corporation. 

The new facility boasts impressive, state-of-the-art refitted laboratories and is approximately three times the floorspace of the previous site. OGT acquired fluorescence in situ hybridisation (FISH) probe manufacturer Cytocell in February 2014 with 30 employees. Since then the company has significantly increased its portfolio, including launching the largest FDA-cleared in vitro diagnostic (IVD) FISH probe range for AML (Acute myeloid Leukaemia) and MDS (Myelodysplastic syndromes) on the market. The number of employees based in Cambridge has increased to 53 and continues to grow, driven by strong double-digit sales growth. As a result, Sysmex has demonstrated its confidence in OGT and the Cytocell brand by expanding operations with the opening of this new facility to cope with increased volume of product manufacture and shipment. In addition, OGT plans to create a training and demonstration facility where customers can benefit from the company’s renowned FISH expertise.

OGT continues to perform well with sustained growth and this investment by Sysmex will accelerate our next phase of product development and global expansion

John Anson

John Anson, CEO of OGT commented, “We are thrilled to celebrate the opening of our state-of-the-art facility in the heart of the Cambridge life science hub. OGT continues to perform well with sustained growth and this investment by Sysmex will accelerate our next phase of product development and global expansion.” 

As well as demonstrating its support for OGT, Sysmex also affirmed its confidence in the UK’s life science industry, by confirming that it will set up a global R&D facility within the OGT laboratories - similar to other sites in Hamburg and Chicago. This facility will serve to evaluate new technologies in the life sciences field and pursue collaborations with key opinion leaders, delivering innovative new products to the market. The facility will also be a hub for networking within the life sciences community, Cambridge University and global healthcare companies.

International Trade Secretary Dr Liam Fox MP said “With a combination of top universities, research institutions, global life sciences companies, increasing government support and world-leading talent, the UK is a fantastic place to invest in research and development. As an international economic department, DIT is determined to boost investment into our life sciences sector and we are pleased to support Sysmex’s significant investment in Cambridge. We are busy forging a vision of the UK as a world-leader in innovation and technology, and aim to make the UK the best place for life sciences businesses to grow.”

Source: Oxford Gene Technology (OGT)


More on the subject:More on companies:
Read all latest stories

Related articles


Sponsored • Sysmex

With the UN-Series, the choice is yours

Using urine to obtain diagnostic insights has been done for thousands of years and still remains an important tool to obtain crucial information. Covering a range of tests, urinalysis may be used to…


Article • Achieving a faster workflow

A modular approach to urinalysis

The reasons why doctors request urinary analysis are varied – perhaps to detect a possible or suspected infection, or to screen for kidney diseases. In all cases a reliable and rapid result is the…


Sponsored • Hematology

Shaping the advancement of healthcare

Our mission at the Sysmex Corporation is defined very clearly in our corporate policy: in all that we do, our focus must be on Shaping the Advancement of Healthcare. Of course, there are a million…

Related products

Subscribe to Newsletter